GENE ONLINE|News &
Opinion
Blog

Anemia
Bristol Myers Squibb Releases Promising Preliminary Anemia Clinical Trial Results
2022-10-31
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
GSK to Acquire Biopharmaceutical Company Sierra Oncology for $1.9B
2022-04-17
European Commission Approves Global Blood Therapeutics’ Oxbryta for Sickle Cell Disease
2022-02-17
Sanofi’ Enjaymo Wins FDA Approval for Rare Autoimmune Anemia
2022-02-07
Vertex to Reap Majority Profits from Gene Editing Deal with CRISPR Therapeutics
2021-04-21
Bluebird Bio Temporarily Suspends Sickle Cell Trials Following Cancer Diagnosis in Two Patients
2021-02-18
Imara’s Sickle Cell Disease Therapy Impresses in Phase 2 Trial
2021-01-09
GeneOnline’s Top 10 Headlines of the Year
2020-12-30
CRISPR Gene-Edited Therapy CTX001 Raises Hopes for Sickle Cell Disease and β-Thalassemia Cures
2020-12-07
CRISPR, Vertex’s Gene Editing Based Therapy, CTX001 Prospers in Hemoglobinopathy Trials
2020-06-18
Celgene, Acceleron’s novel anemia drug gets FDA green light for rare blood disorder
2019-11-11
LATEST
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
Novartis’ Pluvicto Continues Winning Streak In Prostate Cancer Indication
2022-12-07
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
European Commission Continues Fight with Illumina and Orders Grail Acquisition Divestment
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!